X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with J.B.Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs J.B.CHEMICALS - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES J.B.CHEMICALS DIVIS LABORATORIES/
J.B.CHEMICALS
 
P/E (TTM) x 30.0 15.0 200.5% View Chart
P/BV x 5.2 2.4 219.6% View Chart
Dividend Yield % 1.0 0.2 582.0%  

Financials

 DIVIS LABORATORIES   J.B.CHEMICALS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
J.B.CHEMICALS
Mar-16
DIVIS LABORATORIES/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1,222318 384.2%   
Low Rs784200 393.0%   
Sales per share (Unadj.) Rs153.1148.0 103.5%  
Earnings per share (Unadj.) Rs39.919.1 209.3%  
Cash flow per share (Unadj.) Rs44.623.9 186.2%  
Dividends per share (Unadj.) Rs10.000.50 2,000.0%  
Dividend yield (eoy) %1.00.2 516.1%  
Book value per share (Unadj.) Rs201.8128.9 156.5%  
Shares outstanding (eoy) m265.4784.82 313.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.61.7 374.6%   
Avg P/E ratio x25.113.6 185.2%  
P/CF ratio (eoy) x22.510.8 208.1%  
Price / Book Value ratio x5.02.0 247.6%  
Dividend payout %25.02.6 955.5%   
Avg Mkt Cap Rs m266,26621,951 1,213.0%   
No. of employees `0009.72.7 356.1%   
Total wages/salary Rs m4,6871,841 254.6%   
Avg. sales/employee Rs Th4,175.04,590.9 90.9%   
Avg. wages/employee Rs Th481.5673.4 71.5%   
Avg. net profit/employee Rs Th1,089.3592.1 184.0%   
INCOME DATA
Net Sales Rs m40,64312,551 323.8%  
Other income Rs m749542 138.3%   
Total revenues Rs m41,39213,093 316.1%   
Gross profit Rs m14,4602,055 703.8%  
Depreciation Rs m1,233412 299.1%   
Interest Rs m2396 23.6%   
Profit before tax Rs m13,9532,088 668.2%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,349469 714.0%   
Profit after tax Rs m10,6041,619 655.1%  
Gross profit margin %35.616.4 217.3%  
Effective tax rate %24.022.5 106.9%   
Net profit margin %26.112.9 202.3%  
BALANCE SHEET DATA
Current assets Rs m40,1057,778 515.6%   
Current liabilities Rs m6,5954,358 151.3%   
Net working cap to sales %82.527.2 302.6%  
Current ratio x6.11.8 340.8%  
Inventory Days Days11955 216.8%  
Debtors Days Days8180 100.8%  
Net fixed assets Rs m19,9955,713 350.0%   
Share capital Rs m531170 313.0%   
"Free" reserves Rs m53,04310,547 502.9%   
Net worth Rs m53,57410,937 489.8%   
Long term debt Rs m00-   
Total assets Rs m61,58515,574 395.4%  
Interest coverage x618.422.8 2,709.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.8 81.9%   
Return on assets %17.311.0 156.8%  
Return on equity %19.814.8 133.7%  
Return on capital %26.120.0 130.7%  
Exports to sales %048.7 0.0%   
Imports to sales %25.27.1 356.5%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs m10,259889 1,154.4%   
Fx inflow Rs m35,3846,169 573.6%   
Fx outflow Rs m10,3991,285 809.2%   
Net fx Rs m24,9854,884 511.6%   
CASH FLOW
From Operations Rs m11,4931,397 822.9%  
From Investments Rs m-11,372-320 3,550.3%  
From Financial Activity Rs m-93-1,196 7.8%  
Net Cashflow Rs m28-102 -27.8%  

Share Holding

Indian Promoters % 52.0 55.4 93.9%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 11.8 3.4 348.1%  
FIIs % 19.0 3.9 487.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 37.0 46.5%  
Shareholders   31,796 30,437 104.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - PANACEA BIOTECH COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS